

Edurne San Jos©-En©riz

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/376282/publications.pdf>

Version: 2024-02-01

44
papers

2,676
citations

186265

28
h-index

243625

44
g-index

46
all docs

46
docs citations

46
times ranked

4581
citing authors

#	ARTICLE	IF	CITATIONS
1	A network-based approach to integrate nutrient microenvironment in the prediction of synthetic lethality in cancer metabolism. <i>PLoS Computational Biology</i> , 2022, 18, e1009395.	3.2	5
2	Inhibiting Histone and DNA Methylation Improves Cancer Vaccination in an Experimental Model of Melanoma. <i>Frontiers in Immunology</i> , 2022, 13, .	4.8	2
3	Targeting aberrant DNA methylation in mesenchymal stromal cells as a treatment for myeloma bone disease. <i>Nature Communications</i> , 2021, 12, 421.	12.8	29
4	Design and Synthesis of Novel Epigenetic Inhibitors Targeting Histone Deacetylases, DNA Methyltransferase 1, and Lysine Methyltransferase G9a with <i>In Vivo</i> Efficacy in Multiple Myeloma. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 3392-3426.	6.4	11
5	Chromatin activation as a unifying principle underlying pathogenic mechanisms in multiple myeloma. <i>Genome Research</i> , 2020, 30, 1217-1227.	5.5	35
6	Immunogenomic identification and characterization of granulocytic myeloid-derived suppressor cells in multiple myeloma. <i>Blood</i> , 2020, 136, 199-209.	1.4	76
7	Dual Targeting of Histone Methyltransferase G9a and DNA Methyltransferase 1 for the Treatment of Experimental Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 587-603.	7.3	81
8	Inhibition of a G9a/DNMT network triggers immune-mediated bladder cancer regression. <i>Nature Medicine</i> , 2019, 25, 1073-1081.	30.7	125
9	HDAC Inhibitors in Acute Myeloid Leukemia. <i>Cancers</i> , 2019, 11, 1794.	3.7	118
10	COBRA methods and metabolic drug targets in cancer. <i>Molecular and Cellular Oncology</i> , 2018, 5, e1389672.	0.7	3
11	Discovery of Reversible DNA Methyltransferase and Lysine Methyltransferase G9a Inhibitors with Antitumoral <i>In Vivo</i> Efficacy. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6518-6545.	6.4	36
12	Detailed Exploration around 4-Aminoquinolines Chemical Space to Navigate the Lysine Methyltransferase G9a and DNA Methyltransferase Biological Spaces. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 6546-6573.	6.4	19
13	Deregulation of <i>linc-PINT</i> in acute lymphoblastic leukemia is implicated in abnormal proliferation of leukemic cells. <i>Oncotarget</i> , 2018, 9, 12842-12852.	1.8	43
14	Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. <i>Nature Communications</i> , 2017, 8, 15424.	12.8	109
15	<i>In-silico</i> gene essentiality analysis of polyamine biosynthesis reveals APRT as a potential target in cancer. <i>Scientific Reports</i> , 2017, 7, 14358.	3.3	10
16	An <i>in-silico</i> approach to predict and exploit synthetic lethality in cancer metabolism. <i>Nature Communications</i> , 2017, 8, 459.	12.8	35
17	Dual epigenetic modifiers for cancer therapy. <i>Molecular and Cellular Oncology</i> , 2017, 4, e1342748.	0.7	2
18	Reversible dual inhibitor against G9a and DNMT1 improves human iPSC derivation enhancing MET and facilitating transcription factor engagement to the genome. <i>PLoS ONE</i> , 2017, 12, e0190275.	2.5	10

#	ARTICLE	IF	CITATIONS
19	Whole-genome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers. <i>Genome Research</i> , 2015, 25, 478-487.	5.5	118
20	Inhibition of the Methyltransferase G9a with Small Molecules As a New Therapeutic Strategy for Treatment of Hematological Malignancies. <i>Blood</i> , 2014, 124, 3532-3532.	1.4	2
21	Epigenetic regulation of cell signaling pathways in acute lymphoblastic leukemia. <i>Epigenomics</i> , 2013, 5, 525-538.	2.1	13
22	Preclinical activity of LBH589 alone or in combination with chemotherapy in a xenogeneic mouse model of human acute lymphoblastic leukemia. <i>Leukemia</i> , 2012, 26, 1517-1526.	7.2	41
23	Down-regulated expression of hsa-miR-181c in Fanconi anemia patients: implications in TNF α regulation and proliferation of hematopoietic progenitor cells. <i>Blood</i> , 2012, 119, 3042-3049.	1.4	23
24	Román-Gómez J, Cordeu L, Agirre X, Jiménez-Velasco A, San José-Eneriz E, Garate L, Calasanz MJ, Heiniger A, Torres A, Prosper F. Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> . 2007;109(8):3462-3469. <i>Blood</i> , 2012, 120, 3625-3625.	1.4	4
25	Deregulation of <i>FGFR1</i> and <i>CDK6</i> oncogenic pathways in acute lymphoblastic leukaemia harbouring epigenetic modifications of the <i>MIR9</i> family. <i>British Journal of Haematology</i> , 2011, 155, 73-83.	2.5	53
26	Frequent and Simultaneous Epigenetic Inactivation of TP53 Pathway Genes in Acute Lymphoblastic Leukemia. <i>PLoS ONE</i> , 2011, 6, e17012.	2.5	52
27	Epigenetic regulation of the non-canonical Wnt pathway in acute myeloid leukemia. <i>Cancer Science</i> , 2010, 101, 425-432.	3.9	43
28	Epigenetic Regulation of MicroRNAs in Acute Lymphoblastic Leukemia. <i>Journal of Clinical Oncology</i> , 2009, 27, 1316-1322.	1.6	131
29	Epigenetic down-regulation of BIM expression is associated with reduced optimal responses to imatinib treatment in chronic myeloid leukaemia. <i>European Journal of Cancer</i> , 2009, 45, 1877-1889.	2.8	76
30	MicroRNA expression profiling in Imatinib-resistant Chronic Myeloid Leukemia patients without clinically significant ABL1-mutations. <i>Molecular Cancer</i> , 2009, 8, 69.	19.2	101
31	Epigenetic Silencing of the Tumor Suppressor MicroRNA <i>Hsa-miR-124a</i> Regulates CDK6 Expression and Confers a Poor Prognosis in Acute Lymphoblastic Leukemia. <i>Cancer Research</i> , 2009, 69, 4443-4453.	0.9	299
32	Repetitive DNA hypomethylation in the advanced phase of chronic myeloid leukemia. <i>Leukemia Research</i> , 2008, 32, 487-490.	0.8	71
33	Resistance to Imatinib Mesylate-induced apoptosis in acute lymphoblastic leukemia is associated with PTEN down-regulation due to promoter hypermethylation. <i>Leukemia Research</i> , 2008, 32, 709-716.	0.8	39
34	Methylation status of Wnt signaling pathway genes affects the clinical outcome of Philadelphia ϕ -positive acute lymphoblastic leukemia. <i>Cancer Science</i> , 2008, 99, 1865-1868.	3.9	29
35	<i>BCR-ABL1</i> -induced expression of <i>HSPA8</i> promotes cell survival in chronic myeloid leukaemia. <i>British Journal of Haematology</i> , 2008, 142, 571-582.	2.5	33
36	Characterization of the paracrine effects of human skeletal myoblasts transplanted in infarcted myocardium. <i>European Journal of Heart Failure</i> , 2008, 10, 1065-1072.	7.1	119

#	ARTICLE	IF	CITATIONS
37	Down-Regulation of <i>hsa-miR-10a</i> in Chronic Myeloid Leukemia CD34+ Cells Increases USF2-Mediated Cell Growth. <i>Molecular Cancer Research</i> , 2008, 6, 1830-1840.	3.4	208
38	Epigenetic regulation of Wnt-signaling pathway in acute lymphoblastic leukemia. <i>Blood</i> , 2007, 109, 3462-3469.	1.4	153
39	Epigenetic regulation of human cancer/testis antigen gene, HAGE, in chronic myeloid leukemia. <i>Haematologica</i> , 2007, 92, 153-162.	3.5	54
40	WNT5A, a putative tumour suppressor of lymphoid malignancies, is inactivated by aberrant methylation in acute lymphoblastic leukaemia. <i>European Journal of Cancer</i> , 2007, 43, 2736-2746.	2.8	66
41	Epigenetic regulation of PRAME gene in chronic myeloid leukemia. <i>Leukemia Research</i> , 2007, 31, 1521-1528.	0.8	60
42	Downregulation of DBC1 expression in acute lymphoblastic leukaemia is mediated by aberrant methylation of its promoter. <i>British Journal of Haematology</i> , 2006, 134, 137-144.	2.5	30
43	Promoter hypermethylation and global hypomethylation are independent epigenetic events in lymphoid leukemogenesis with opposing effects on clinical outcome. <i>Leukemia</i> , 2006, 20, 1445-1447.	7.2	46
44	CpG Island Methylator Phenotype Redefines the Prognostic Effect of t(12;21) in Childhood Acute Lymphoblastic Leukemia. <i>Clinical Cancer Research</i> , 2006, 12, 4845-4850.	7.0	62